GCRI · 生物技术与生物安全
生物技术与生物安全中的生物技术平台
How biotechnology platforms is applied in Biotechnology and Biosecurity. Biotechnology platforms apply biological 系统 to produce medicines, diagnostics, materials and agricultural products. They expand response capacity for health threats while introducing dual-use and biosafety concerns.
What biotechnology platforms does here.
Biotechnology platforms apply biological 系统 to produce medicines, diagnostics, materials and agricultural products. They expand response capacity for health threats while introducing dual-use and biosafety concerns. In health and biosecurity and food and agriculture, biotechnology capacity shapes how quickly countermeasures can be produced in a crisis. Its supply chains and dual-use potential are part of biosecurity planning. The canonical description is on STEM Commons.
- 01
Methods used here
genetic engineering; bioprocess design; high-throughput screening; diagnostic assay development; vaccine platform development; biosafety 风险评估.
- 02
验证
Products are evaluated through staged preclinical and clinical testing and manufacturing quality controls. Regulatory review and independent replication check claims.
地点网络上的 SEIR 模型。
An outbreak seeded in one place spreads through a small-world network by the share of contacts people make elsewhere; play it to see the order of arrival and how the timing of measures moves the peak. Teaching model with stated illustrative values, not a prediction.
控制措施
- 基本再生数 R0
- 2.5
- 潜伏期
- 3.0 days
- 传染期
- 5.0 days
- 在其他地点发生的接触所占比例
- 8%
- 网络中的地点
- 24
- 措施开始于第几天
- 40
- 措施带来的接触减少
- 40%
- 模拟天数
- 240 days
读数
- 新增感染峰值
- 3.97 per 1,000 a day
- 峰值日
- 122
- 累计感染比例
- 54%
- 已覆盖地点
- 100%
- 采取措施后的再生数
- 1.50
数字、方法与来源
| 日 | 每 1,000 人新增感染 | 累计感染（%） |
|---|---|---|
| 0 | 0.00 | 0.0 |
| 17 | 0.02 | 0.0 |
| 34 | 0.21 | 0.2 |
| 51 | 0.66 | 1.0 |
| 68 | 1.33 | 2.6 |
| 85 | 2.32 | 5.8 |
| 102 | 3.38 | 10.7 |
| 119 | 3.96 | 17.1 |
| 136 | 3.77 | 23.7 |
| 153 | 3.32 | 29.7 |
| 170 | 3.09 | 35.1 |
| 187 | 3.03 | 40.3 |
| 204 | 2.90 | 45.3 |
| 221 | 2.53 | 50.0 |
| 238 | 1.86 | 53.7 |
方法
- SEIR 仓室 Kermack 和 McKendrick（1927），Proc. R. Soc. A 115
- 通过人口流动实现的集合种群耦合 Balcan and others (2009), PNAS 106
- 小世界网络 Watts and Strogatz (1998), Nature 393
- 传染病建模 Keeling and Rohani (2008), Princeton University Press
- 不确定性扇形图（参数蒙特卡罗） Spiegelhalter, Pearson and Short (2011), Visualising uncertainty about the future, Science 333
- 单因素敏感性（龙卷风图） Saltelli and others (2008), Global Sensitivity Analysis: The Primer, Wiley
数据
The model runs on the teaching values set by the controls. To calibrate it for a place, read it against these admitted layers and series, which this page’s map can draw:
- 城市 Natural Earth
- 机场 Natural Earth
- 主要道路 Natural Earth
贯穿六大支柱，由 Nexus Consortium 牵头
该方法使用的输入。
Datasets and records used by biotechnology platforms on this platform, with the role each plays and the label its values carry. Sources are listed in 来源登记册.
| 数据 | 角色 | 标签 |
|---|---|---|
| Laboratory automation 系统 | 输入 | 观测 |
| Bioreactor process data | 输入 | 观测 |
| Clinical trial registries | 输入 | 观测 |
| Genomic databases | 输入 | 观测 |
| Manufacturing quality records | 输入 | 观测 |
The model, the data and the uncertainty.
模型、其假设、数据和不确定性，以科学家或工程师会核查的形式呈现。结构遵循已发表的方法。所取数值仅为示意，不是研究发现。
不确定性区间
How far the outlook for Biotechnology platforms at Biotechnology and Biosecurity could spread, shown as ranges rather than a single line.
- 中心估计值
- 集合的中位数
- 范围
- IPCC 校准用语中的“可能”和“很可能”
- 集合
- 明示成员、情景和初始条件
- 配合阅读
- 结果对每项输入的敏感性
结果如何核查。
Products are evaluated through staged preclinical and clinical testing and manufacturing quality controls. Regulatory review and independent replication check claims.
Scale-up from laboratory to production often fails or takes time. Containment and oversight can lag behind technical capability.
由谁维护该方法。
Biotechnology and Biosecurity stewards biotechnology platforms for the Consortium and reviews how it is applied across platforms.
问题与解答。
What are the limits of biotechnology platforms in this field?
结果如何核查？
本页面上的数值是真实的吗？
该方法还应用于何处？
从本页贡献证据。
报告 is the Consortium’s quarterly publication. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work.
- 电子邮件网关 GW-GCRI从本页发送证据、更正、案例、方法、审查、翻译或概况投稿。它会带上本页标签送达，由负责的编辑接收。
- Zenodo开放存缴存缴并提交到社区用您的 ORCID iD 在 Zenodo 上发布您自己的记录，然后提交到那里的 Reports 社区。由策展人审核；DOI 仍归您所有。
- 报告GCRI查看所有贡献方式贡献类型、各自的评审方式、您获得的署名、许可协议，以及绝不接受的内容。
切勿发送个人数据、敏感基础设施细节或您无权分享的任何内容。贡献在使用前会经过审查；发送贡献不赋予署名权或编辑权，赞助也绝不能换取研究结论。
法律文件。
本网站上的地图、数据和图表仅作为背景和一般信息展示。它们不是建议、预测或预警；信息的局限见免责声明和数据说明。